Description
Why It’s Done:
This test is done to:
• Monitor disease progression or remission in patients receiving treatment for CML or Ph+ ALL
• Assess treatment effectiveness, particularly with TKIs like imatinib, dasatinib, or nilotinib
• Detect minimal residual disease that may indicate relapse
• Guide treatment adjustments based on the level of BCR-ABL transcripts
Preparation:
• No special preparation such as fasting is required.
• A blood sample is collected, typically from a vein.
• Inform your healthcare provider about recent treatments or medications.
• Regular testing intervals may be recommended to closely monitor disease status.


